论文部分内容阅读
目的:研究糖皮质激素、β受体激动剂、胆碱能受体拮抗剂联合吸入在难治性哮喘治疗中的价值。方法:将我院收治的难治性哮喘患者纳入研究,根据治疗方法不同分为给予糖皮质激素、β受体激动剂吸入治疗的对照组以及糖皮质激素、β受体激动剂、胆碱能受体拮抗剂联合吸入治疗的观察组,比较两组患者的气道功能。结果:观察组患者的PEF、FEV1/FVC%均高于对照组,PEF昼夜变异率低于对照组。结论:糖皮质激素、β受体激动剂、胆碱能受体拮抗剂联合吸入有助于改善气道功能,是治疗支气管哮喘的理想方法。
Objective: To study the value of glucocorticoid, β-agonist and cholinergic receptor antagonist inhalation in the treatment of refractory asthma. Methods: The patients with refractory asthma admitted to our hospital were included in the study. According to the different treatment methods, they were divided into three groups: control group receiving glucocorticoid and inhaled β-agonist, glucocorticoid, β-agonist, cholinergic Receptor antagonist combined with inhalation therapy in the observation group, compared two groups of patients with airway function. Results: The PEF and FEV1 / FVC% of the observation group were higher than that of the control group, and the day-night mutation rate of PEF was lower than that of the control group. CONCLUSION: Glucocorticoid, beta-agonist and cholinergic receptor antagonist combined with inhalation can help to improve airway function and is an ideal treatment for bronchial asthma.